MedPath

Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy

Phase 4
Conditions
Prostate Cancer
Interventions
Device: RapidStrand seeds for use with 18g needle
Device: ThinStrand
Registration Number
NCT01379742
Lead Sponsor
Prostate Cancer Foundation of Chicago
Brief Summary

This study will investigate health related quality of life factors in patients undergoing low dose rate prostate brachytherapy. Patients will be randomized to Iodine-125 Thinstrand (for use with 20 g needles) or Rapidstrand (for use with standard 18 g needles). Urinary, bowel, sexual function and bother will be measured by the EPIC questionnaire at various time intervals.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
240
Inclusion Criteria
  • Histologically confirmed adenocarcinoma of the prostate, clinical stage T1c - T2b, N0, M0
  • Greater than or equal to 40 years of age
  • Low and Low- Intermediate Risk prostate cancer
  • Prostate volumes by TRUS ≤ 60 cc
  • I-PSS score < 25 (alpha blockers allowed)
  • Signed study-specific informed consent form prior to study entry
Exclusion Criteria
  • Lymph node involvement (N1)
  • Evidence of distant metastases (M1)
  • Radical surgery for carcinoma of the prostate
  • Prior pelvic radiation
  • Major medical or psychiatric illness, which in the investigator's opinion would prevent completion of treatment and would interfere with follow- up or ability to complete questionnaires
  • Hip prosthesis
  • Inability or refusal to provide informed consent
  • Evidence of Previous TURP
  • Prior hormone therapy
  • Prior TURP

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Iodine-125 standard 18 g needleThinStrandRapidstrand
20 g needleRapidStrand seeds for use with 18g needleThin Strand
Iodine-125 standard 18 g needleRapidStrand seeds for use with 18g needleRapidstrand
20 g needleThinStrandThin Strand
Primary Outcome Measures
NameTimeMethod
Health related quality of life including urinary, bowel and sexual function as measured by the EPIC questionnaire1 year

Randomized

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Chicago Prostate Center

🇺🇸

Westmont, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath